Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.49 |
| ▸ | CDC25B | P30305 | 9/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.49 |
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913250 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL13599703 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15873498 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15873543 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15873499 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL17320861 | 0.90 | NT5E (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15873553 | 0.87 | TACR2 (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15873551 | 0.87 | TACR2 (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15873531 | 0.87 | TACR2 (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL18393101 | 0.87 | TACR2 (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3530663-B1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | SUNSHINE BIOPHARMA INC (CA) | 2021-08-11 | — | — | EP | disclosed |
| EP-3530663-A1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | Advanomics Corp. (CA) | 2019-08-28 | — | — | EP | disclosed |
| EP-3530663-A1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | Advanomics Corp. (CA) | 2019-08-28 | — | — | EP | disclosed |
| US-10272065-B2 | Gem-difluorinated C-glycoside compounds as anti-cancer agents | Benoit & Côté (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10272065-B2 | Gem-difluorinated C-glycoside compounds as anti-cancer agents | Benoit & Côté (CA) | 2019-04-30 | — | — | US | disclosed |
| US-20150353573-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | ADVANOMICS CORPORATION (CA) | 2015-12-10 | — | — | US | disclosed |
| EP-2943497-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | Advanomics Corp. (CA) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014107803-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | ADVANOMICS CORPORATION (CA) | 2014-07-17 | — | — | WO | disclosed |
| US-8236935-B2 | Gem-difluorinated C-glycoside compounds derived from podophyllotoxin, their preparation and their applications | INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090318675-A1 | NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS | SUNSHINE BIOPHARMA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353573-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | GMNN, DDOST, MAGT1 | NT5E 3883/4885PTPN1 2020/4885CDC25B 253/4885 |
| US-20090318675-A1 | NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS | GLRA3, GMNN, B3GAT3 | NT5E 4331/4885PTPN1 962/4885CDC25B 1093/4885 |
| US-10272065-B2 | Gem-difluorinated C-glycoside compounds as anti-cancer agents | GMNN, DDOST, MAGT1 | NT5E 3883/4885PTPN1 2020/4885CDC25B 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.